Prothena (PRTA) Shares Surge On Positive Results From Phase 1 Study of PRX002

Prothena Corporation plc (PRTA) shares are trading higher by nearly 28% to $37.40 in the extended session Thursday after the company announced positive results from a Phase 1 single ascending dose study of PRX002, a monoclonal antibody for the potential treatment of Parkinson’s disease and other related synucleinopathies. PRX002 is the focus of a worldwide […] View the full post at: Prothena (PRTA) Shares Surge On Positive Results From Phase 1 Study of PRX002 Related posts: Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale American Southern Bank Goes Bust